Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Contraceptives, Anti-Depressants, Insulin Sensitizing Agents, Diuretics, Aromatase Inhibitors, Ornithine Decarboxylase Inhibitors); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00004072 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

PCOS, or polycystic ovary syndrome, is a hormonal disorder that affects a large percentage of women of childbearing age. PCOS is characterised by irregular or prolonged menstrual cycles, as well as elevated amounts of male hormones. Although there is currently there is no cure for PCOS, various medications are used to regulate the menstrual cycle and manage the symptoms of the disease. The polycystic ovarian syndrome treatment sector is booming owing to an increase in the prevalence of PCOS, increased patient awareness, and increased usage of combination therapy. Furthermore, market market is fueled by easier access to PCOS treatments, rising demand for PCOS drugs, and technological advancements for PCOS diagnosis.

MARKET SCOPE

The "Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the polycystic ovarian syndrome (PCOS) treatment market with detailed market segmentation by drug class and distribution channel. The report provides key statistics on the market status of the leading polycystic ovarian syndrome (PCOS) treatment market players and offers key trends and opportunities in the market.MARKET SEGMENTATION

  •   Based on drug class the market is segmented as, contraceptives, anti-depressants, insulin sensitizing agents, diuretics, aromatase inhibitors and ornithine decarboxylase inhibitors.
  •   Based on distribution channel the market is segmented as, hospital pharmacies, retail pharmacies and online pharmacies.

MARKET DYNAMICS
Drivers:

  •   Increasing prevalence of PCOS is the key driver for the market growth.
  •   Growing awareness about PCOS and its treatment.
  •   Adoption of combination therapies for PCOS, technological advancements in screening of PCOS.
  •   Extensive R&D efforts to develop effective therapies for treatment of PCOS.

Restraints:

  •   However, lack of specific treatment for PCOS, lack of approved therapeutics are the restraining factors for the market growth.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The polycystic ovarian syndrome (PCOS) treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the polycystic ovarian syndrome (PCOS) treatment market in these regions.

IMPACT OF COVID-19 ON POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS

The report covers key developments in the polycystic ovarian syndrome (PCOS) treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from polycystic ovarian syndrome (PCOS) treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for polycystic ovarian syndrome (PCOS) treatment in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the polycystic ovarian syndrome (PCOS) treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
  •   Teva Pharmaceutical Industries Ltd.
  •   Mylan N.V.
  •   Sanofi
  •   Novartis AG
  •   Merck KGaA
  •   Bristol-Myers Squibb Company
  •   AstraZeneca
  •   ADDEX THERAPEUTICS
  •   Ferring B.V
  •   Bayer AG
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
  • TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Polycystic Ovarian Syndrome (PCOS) Treatment Market - By Drug Class
    1.3.2 Polycystic Ovarian Syndrome (PCOS) Treatment Market - By Distribution Channel
    1.3.3 Polycystic Ovarian Syndrome (PCOS) Treatment Market - By Region
    1.3.3.1 By Country

    2. KEY TAKEAWAYS

    3. RESEARCH METHODOLOGY

    4. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PORTER'S FIVE FORCES ANALYSIS
    4.2.1 Bargaining Power of Buyers
    4.2.1 Bargaining Power of Suppliers
    4.2.1 Threat of Substitute
    4.2.1 Threat of New Entrants
    4.2.1 Competitive Rivalry
    4.3. EXPERT OPINIONS

    5. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

    6. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - GLOBAL MARKET ANALYSIS
    6.1. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT - GLOBAL MARKET OVERVIEW
    6.2. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE

    7. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
    7.1. OVERVIEW
    7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
    7.3. CONTRACEPTIVES
    7.3.1. Overview
    7.3.2. Contraceptives Market Forecast and Analysis
    7.4. ANTI-DEPRESSANTS
    7.4.1. Overview
    7.4.2. Anti-Depressants Market Forecast and Analysis
    7.5. INSULIN SENSITIZING AGENTS
    7.5.1. Overview
    7.5.2. Insulin Sensitizing Agents Market Forecast and Analysis
    7.6. DIURETICS
    7.6.1. Overview
    7.6.2. Diuretics Market Forecast and Analysis
    7.7. AROMATASE INHIBITORS
    7.7.1. Overview
    7.7.2. Aromatase Inhibitors Market Forecast and Analysis
    7.8. ORNITHINE DECARBOXYLASE INHIBITORS
    7.8.1. Overview
    7.8.2. Ornithine Decarboxylase Inhibitors Market Forecast and Analysis
    8. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
    8.1. OVERVIEW
    8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
    8.3. HOSPITAL PHARMACIES
    8.3.1. Overview
    8.3.2. Hospital Pharmacies Market Forecast and Analysis
    8.4. RETAIL PHARMACIES
    8.4.1. Overview
    8.4.2. Retail Pharmacies Market Forecast and Analysis
    8.5. ONLINE PHARMACIES
    8.5.1. Overview
    8.5.2. Online Pharmacies Market Forecast and Analysis

    9. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    9.1. NORTH AMERICA
    9.1.1 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
    9.1.2 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
    9.1.3 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
    9.1.4 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
    9.1.5 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
    9.1.5.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.1.5.1.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.1.5.1.2 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.1.5.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.1.5.2.1 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.1.5.2.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.1.5.3 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.1.5.3.1 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.1.5.3.2 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.2. EUROPE
    9.2.1 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
    9.2.2 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
    9.2.3 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
    9.2.4 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
    9.2.5 Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
    9.2.5.1 Germany Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.2.5.1.1 Germany Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.2.5.1.2 Germany Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.2.5.2 France Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.2.5.2.1 France Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.2.5.2.2 France Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.2.5.3 Italy Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.2.5.3.1 Italy Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.2.5.3.2 Italy Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.2.5.4 Spain Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.2.5.4.1 Spain Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.2.5.4.2 Spain Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.2.5.5 United Kingdom Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.2.5.5.1 United Kingdom Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.2.5.5.2 United Kingdom Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.2.5.6 Rest of Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.2.5.6.1 Rest of Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.2.5.6.2 Rest of Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.3. ASIA-PACIFIC
    9.3.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
    9.3.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
    9.3.3 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
    9.3.4 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
    9.3.5 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
    9.3.5.1 Australia Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.3.5.1.1 Australia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.3.5.1.2 Australia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.3.5.2 China Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.3.5.2.1 China Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.3.5.2.2 China Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.3.5.3 India Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.3.5.3.1 India Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.3.5.3.2 India Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.3.5.4 Japan Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.3.5.4.1 Japan Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.3.5.4.2 Japan Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.3.5.5 South Korea Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.3.5.5.1 South Korea Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.3.5.5.2 South Korea Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.3.5.6 Rest of Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.3.5.6.1 Rest of Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.3.5.6.2 Rest of Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.4. MIDDLE EAST AND AFRICA
    9.4.1 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
    9.4.2 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
    9.4.3 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
    9.4.4 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
    9.4.5 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
    9.4.5.1 South Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.4.5.1.1 South Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.4.5.1.2 South Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.4.5.2 Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.4.5.2.1 Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.4.5.2.2 Saudi Arabia Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.4.5.3 U.A.E Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.4.5.3.1 U.A.E Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.4.5.3.2 U.A.E Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.4.5.4 Rest of Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.4.5.4.1 Rest of Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.4.5.4.2 Rest of Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.5. SOUTH AND CENTRAL AMERICA
    9.5.1 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
    9.5.2 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis
    9.5.3 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Drug Class
    9.5.4 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Distribution Channel
    9.5.5 South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecasts and Analysis - By Countries
    9.5.5.1 Brazil Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.5.5.1.1 Brazil Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.5.5.1.2 Brazil Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.5.5.2 Argentina Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.5.5.2.1 Argentina Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.5.5.2.2 Argentina Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel
    9.5.5.3 Rest of South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market
    9.5.5.3.1 Rest of South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market by Drug Class
    9.5.5.3.2 Rest of South and Central America Polycystic Ovarian Syndrome (PCOS) Treatment Market by Distribution Channel

    10. INDUSTRY LANDSCAPE
    10.1. MERGERS AND ACQUISITIONS
    10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    10.3. NEW PRODUCT LAUNCHES
    10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    11. POLYCYSTIC OVARIAN SYNDROME (PCOS) TREATMENT MARKET, KEY COMPANY PROFILES
    11.1. SANOFI
    11.1.1. Key Facts
    11.1.2. Business Description
    11.1.3. Products and Services
    11.1.4. Financial Overview
    11.1.5. SWOT Analysis
    11.1.6. Key Developments
    11.2. NOVARTIS AG
    11.2.1. Key Facts
    11.2.2. Business Description
    11.2.3. Products and Services
    11.2.4. Financial Overview
    11.2.5. SWOT Analysis
    11.2.6. Key Developments
    11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD.
    11.3.1. Key Facts
    11.3.2. Business Description
    11.3.3. Products and Services
    11.3.4. Financial Overview
    11.3.5. SWOT Analysis
    11.3.6. Key Developments
    11.4. MERCK KGAA
    11.4.1. Key Facts
    11.4.2. Business Description
    11.4.3. Products and Services
    11.4.4. Financial Overview
    11.4.5. SWOT Analysis
    11.4.6. Key Developments
    11.5. BRISTOL-MYERS SQUIBB COMPANY
    11.5.1. Key Facts
    11.5.2. Business Description
    11.5.3. Products and Services
    11.5.4. Financial Overview
    11.5.5. SWOT Analysis
    11.5.6. Key Developments
    11.6. ASTRAZENECA
    11.6.1. Key Facts
    11.6.2. Business Description
    11.6.3. Products and Services
    11.6.4. Financial Overview
    11.6.5. SWOT Analysis
    11.6.6. Key Developments
    11.7. ADDEX THERAPEUTICS
    11.7.1. Key Facts
    11.7.2. Business Description
    11.7.3. Products and Services
    11.7.4. Financial Overview
    11.7.5. SWOT Analysis
    11.7.6. Key Developments
    11.8. MYLAN N.V
    11.8.1. Key Facts
    11.8.2. Business Description
    11.8.3. Products and Services
    11.8.4. Financial Overview
    11.8.5. SWOT Analysis
    11.8.6. Key Developments
    11.9. FERRING B.V
    11.9.1. Key Facts
    11.9.2. Business Description
    11.9.3. Products and Services
    11.9.4. Financial Overview
    11.9.5. SWOT Analysis
    11.9.6. Key Developments
    11.10. BAYER AG
    11.10.1. Key Facts
    11.10.2. Business Description
    11.10.3. Products and Services
    11.10.4. Financial Overview
    11.10.5. SWOT Analysis
    11.10.6. Key Developments

    12. APPENDIX
    12.1. ABOUT THE INSIGHT PARTNERS
    12.2. GLOSSARY OF TERMS
    The List of Companies

    1. Sanofi
    2. Novartis AG
    3. Teva Pharmaceutical Industries Ltd.
    4. Merck KGaA
    5. Bristol-Myers Squibb Company
    6. AstraZeneca
    7. ADDEX THERAPEUTICS
    8. Mylan N.V
    9. Ferring B.V
    10. Bayer AG
    TIPRE00004072
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Pricing

    Free

    20%

    customization on Pre-Booking